Does hemolysis occur in an O positive mother with a B positive baby?

ABO Hemolytic Disease in O Positive Mother with B Positive Baby

Yes, hemolysis can occur when an O positive mother delivers a B positive baby, though it is typically mild and manageable with phototherapy alone. This represents classic ABO hemolytic disease of the newborn (ABO-HDN), which occurs because group O mothers naturally produce IgG anti-A and anti-B antibodies that can cross the placenta and attack fetal red blood cells carrying A or B antigens 1, 2.

Understanding the Mechanism

• The Rh (positive) status is irrelevant to this scenario - ABO incompatibility and Rh incompatibility are completely separate systems. The mother being O positive and baby being B positive means there is no Rh incompatibility, so Rh-mediated hemolysis will not occur 3.

• ABO incompatibility is the most common cause of hemolytic disease of the newborn, affecting 1 in 150 to 1 in 3,000 births depending on severity 1.

• Group O mothers produce IgG anti-A,B antibodies (in addition to IgM forms) that can cross the placenta, whereas group A or B mothers typically produce predominantly IgM antibodies that cannot cross 1, 2.

Clinical Severity and Expected Course

• ABO-HDN is nearly always mild compared to Rh hemolytic disease, with most cases successfully managed with phototherapy alone and rarely requiring exchange transfusion 1, 2.

• The typical presentation includes:

  • Jaundice developing in the first 24-48 hours of life 1, 2
  • Mild to moderate anemia 1
  • Positive direct antiglobulin test (DAT) from anti-B antibodies 2
  • Escalating hyperbilirubinemia requiring phototherapy in most cases 1, 2

Risk Factors for Severe Disease

• High maternal IgG anti-B titers (>256) significantly increase the risk of severe hemolysis requiring exchange transfusion 2, 4.

• African American ethnicity has been associated with more aggressive hemolysis in some case reports 1, 2.

• Maternal anti-A/B IgG titers measured at birth have good predictive value: negative predictive value of 0.93 and positive predictive value of 0.73 for clinically significant hyperbilirubinemia 4.

Management Approach

• Obtain a DAT on the newborn's cord blood or early postnatal sample - a positive DAT confirms immune-mediated hemolysis 1, 2.

• Monitor total serum bilirubin or transcutaneous bilirubin levels and plot on hour-specific nomogram to determine risk zone 5.

• Use standard phototherapy thresholds based on gestational age and postnatal age - do not use the lower thresholds reserved for Rh hemolytic disease unless the clinical course is severe 5.

• Monitor hemoglobin levels, as newborn hemoglobin is significantly lower in ABO-incompatible infants compared to compatible controls 4.

• Exchange transfusion is rarely needed but should be performed if bilirubin levels meet established criteria despite intensive phototherapy 2.

Critical Pitfalls to Avoid

• Do not assume ABO-HDN is always benign - while rare, severe cases requiring exchange transfusion do occur, particularly with very high maternal antibody titers 2.

• If the DAT is negative in an O mother/B baby pair with significant jaundice, actively search for alternative causes such as glucose-6-phosphate dehydrogenase deficiency 5.

• Do not confuse this with Rh disease - the positive Rh status in both mother and baby means Rh incompatibility is not a factor 3.

• Ensure close follow-up within 24-48 hours if discharged before 72 hours of life, as peak bilirubin typically occurs at 3-5 days 5.